During the last session, Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s traded shares were 4.32 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $11.33, reflecting an intraday loss of -0.61% or -$0.07. The 52-week high for the IOVA share is $18.33, that puts it down -61.78 from that peak though still a striking 71.67% gain since the share price plummeted to a 52-week low of $3.21. The company’s market capitalization is $3.44B, and the average intraday trading volume over the past 10 days was 6.2 million shares, and the average trade volume was 7.41 million shares over the past three months.
Iovance Biotherapeutics Inc (IOVA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.46. IOVA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.3.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Iovance Biotherapeutics Inc (IOVA) registered a -0.61% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.61% in intraday trading to $11.33, hitting a weekly high. The stock’s 5-day price performance is -4.23%, and it has moved by 26.45% in 30 days. Based on these gigs, the overall price performance for the year is 85.13%. The short interest in Iovance Biotherapeutics Inc (NASDAQ:IOVA) is 59.33 million shares and it means that shorts have 7.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 50.74% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $40 respectively. As a result, IOVA is trading at a discount of -253.05% off the target high and 47.04% off the low.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Statistics show that Iovance Biotherapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Iovance Biotherapeutics Inc (IOVA) shares have gone down -35.00% during the last six months, with a year-to-date growth rate more than the industry average at 33.33% against 18.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 34.80% this quarter and then jump 40.00% in the quarter after that. In the rating firms’ projections, revenue will increase 13,563.60% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 53.79M as predicted by 12 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 77.18M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 469k and 482k respectively. In this case, analysts expect current quarter sales to grow by 11,369.10% and then jump by 15,912.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -8.25%. While earnings are projected to return 31.97% in 2024.
IOVA Dividends
Iovance Biotherapeutics Inc is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Iovance Biotherapeutics Inc insiders own 0.50% of total outstanding shares while institutional holders control 87.31%, with the float percentage being 87.75%. VANGUARD GROUP INC is the largest shareholder of the company, while 391.0 institutions own stock in it. As of 2024-06-30, the company held over 25.95 million shares (or 9.7478% of all shares), a total value of $208.12 million in shares.
The next largest institutional holding, with 25.93 million shares, is of PERCEPTIVE ADVISORS LLC’s that is approximately 9.7412% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $207.98 million.
